Chromocell Therapeutics Corp Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2023 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Chromocell Therapeutics Corp quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2023 to Q1 2024.
  • Chromocell Therapeutics Corp Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $5.67M, a 3295% increase year-over-year.
  • Chromocell Therapeutics Corp annual Net Cash Provided by (Used in) Financing Activities for 2023 was $1.02M, a 37% decline from 2022.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $5.67M +$5.5M +3295% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q1 2023 $167K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.